-
17β-HSD Related Products (144)
Related Products (144)
-
HSD17B13-IN-99
0 ImagesCat. No.: HY-162225CAS No.: 2849338-46-9HSD17B13-IN-99 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-99 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
HSD17B13-IN-22
0 ImagesCat. No.: HY-157653CAS No.: 2919797-60-5HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma.
-
HSD17B13-IN-60
0 ImagesCat. No.: HY-163257CAS No.: 2770247-20-4HSD17B13-IN-60 (Compound 126) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-60 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
HSD17B13-IN-101
0 ImagesCat. No.: HY-162278HSD17B13-IN-101 is a selective inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for Estradiol is <0.1 μM. HSD17B13-IN-101 can be used in the study of nonalcoholic fatty liver disease (NAFLD) (WO2023146897A1; compound 94).
-
GPI2A sodium scrambled negative control
0 ImagesCat. No.: HY-177636BGPI2A sodium scrambled negative control is the sequence scrambled negative control of GPI2A sodium.
-
(±)-Naproxen-13C,d3-1
0 ImagesCat. No.: HY-W777599CAS No.: 1216704-11-8Synonyms: (Rac)-Naproxen-13C,d3-1(±)-Naproxen-13C,d3-1 ((Rac)-Naproxen-13C,d3-1) is the deuterated, 13C-labeled (±)-Naproxen (HY-15029). (±)-Naproxen ((Rac)-Naproxen) is the racemate of Naproxen (HY-15030), consisting of R- and S-enantiomers. (±)-Naproxen binds to AKR1C3, which preferentially recognizes the R-enantiomer from the racemic mixture. It is used for AKR1C3 stereoselective ligand recognition and studies on NSAID binding mechanisms.
-
HSD17B13-IN-18
0 ImagesCat. No.: HY-161219CAS No.: 2758802-14-9HSD17B13-IN-18 (compound 13) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-18? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-94
0 ImagesCat. No.: HY-162220CAS No.: 2848620-90-4HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI).
-
HSD17B13-IN-78
0 ImagesCat. No.: HY-161231CAS No.: 2770246-21-2HSD17B13-IN-78 (22) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
-
HSD17B13-IN-56-d3
0 ImagesCat. No.: HY-163253SCAS No.: 2770247-60-2HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
HSD17B13-IN-36
0 ImagesCat. No.: HY-157663CAS No.: 2730027-86-6HSD17B13-IN-36 (compound 116) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-36? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
-
HSD17B13-IN-85
0 ImagesCat. No.: HY-162212CAS No.: 2770247-76-0HSD17B13-IN-85 (186) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
-
FXR/HSD17B13-modulator-2
0 ImagesCat. No.: HY-183309FXR/HSD17B13-modulator-2 is a dual FXR activator and HSD17B13 inhibitor with human FXR EC50 of 128 nM, human HSD17B13 IC50 of 0.18 μM, high selectivity over related nuclear receptors and HSD17B isoforms, and oral effectiveness.FXR/HSD17B13-modulator-2 alleviates fatty liver, regulates lipid metabolism, reduces inflammation, and attenuates hepatic fibrosis.FXR/HSD17B13-modulator-2 is the first non-carboxylic acid dual FXR/HSD17B13 modulator.FXR/HSD17B13-modulator-2 can be used for the research of metabolic dysfunction-associated steatohepatitis.
-
HSD17B13-IN-5
0 ImagesCat. No.: HY-157613HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).
-
HSD17B13-IN-84
0 ImagesCat. No.: HY-162211CAS No.: 2770247-73-7HSD17B13-IN-84 (182) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
-
HSD17B13-IN-4
0 ImagesCat. No.: HY-157601HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI).
-
HSD17B13-IN-98
0 ImagesCat. No.: HY-162224CAS No.: 2849338-45-8HSD17B13-IN-98 (5) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC50 value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease.
-
HSD17B13-IN-59
0 ImagesCat. No.: HY-163256CAS No.: 2770247-11-3HSD17B13-IN-59 (Compound 177) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-59 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
-
7-Coumaryl triflate
0 ImagesCat. No.: HY-43322CAS No.: 108530-10-57-Coumaryl triflate is a type 17β-HSD1 inhibitor of 17β-hydroxysteroid dehydrogenase. Its IC50 is 360 nM and Ki is 173 nM. 7-Coumaryl triflate shows selectivity for 17β-HSD2 and has no detectable affinity for ERα or ERβ. 7-Coumaryl triflate can be used in related research on hormone-dependent breast cancer.
-
HSD17B13-IN-26
0 ImagesCat. No.: HY-157654CAS No.: 2919797-61-6HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma.
